Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorXiaotong Hou
About this trial
The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.
Eligibility criteria
Qualifiers
Age ≥ 18 years old
Accept VA-ECMO or VV-ECMO
the ECMO team believes that systemic anticoagulation is necessary and that APTT should be maintained at 40-60s.
sign the informed consent form
Disqualifiers
previous history of allergy to heparin or bivalirudin
previous diagnosis of heparin-induced thrombocytopenia.
the pre-random ECMO assistance time is more than 48 hours.
pregnant female
Trial design
Treatments tested in this trial
- bivalirudin
- unfractionated heparin
Treatment groups
154 Participants
are divided into 2 treatment groupsSponsors and collaborators
Xiaotong Hou
Lead sponsor
Beijing Anzhen Hospital
Sponsor institution
Source ClinicalTrials.gov